Chronic Obstructive Pulmonary Disease (COPD) Therapeutics

Aug. 10, 2011 - PRLog -- GlobalData estimated the chronic obstructive pulmonary disease (COPD) therapeutics market to be worth $9.2 billion in 2010 and projects it to grow at a compound annual growth rate (CAGR) of 3.8% to reach $12.5 billion in 2018. The patent expiry of major blockbuster drugs, such as Spiriva (tiotropium) and Advair/Seretide (fluticasone propionate and salmeterol fixed dose combination), is expected to alter the momentum of growth in the near future. However, the development of novel once-daily inhaled therapies is expected to offer new treatment options for COPD patients, and will play a major role in the expansion of the COPD market in the future. In the major markets, a steady increase in the prevalence rate, disease awareness and injurious environmental factors has led to significant growth in the COPD therapeutics market.

GlobalData’s analysis shows that the currently marketed drugs are able to meet the market demand moderately in terms of efficacy, offering symptomatic relief but not a cure for the disease. However, the
drugs are good in terms of meeting safety parameters. COPD therapies mainly consist of inhalation bronchodilators that need to be administered three to four times daily over the treatment period, which
has been a major concern in leading to poor compliance. There is a major unmet need for effective disease modifying therapies that target the underlying pathophysiology of COPD, whilst improving lung
function and the quality of life for COPD patients.

GlobalData’s analysis shows that current treatment options are able to meet the expectations in terms of safety and efficacy to a certain extent. However, short duration of action and the need for frequent dosing has been a major limitation, which remains an unmet need and provides potential for new entrants. A new entrant that can offer a longer duration of action, less frequent dosing and improved efficacy and safety profiles will have significant market potential.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

GlobalData’s analysis reveals that the COPD development pipeline is strong, with 121 molecules in the
various stages of development. The late stage pipeline consists of 16 molecules that are mainly me-too
molecules and fixed dose combinations. Aclidinium bromide, glycopyrronium bromide, QVA149 (indacaterol and glycopyrronium bromide fixed dose combination), Relovair (vilanterol and fluticasone
furoate fixed dose combination), GW642444 (vilanterol trifenatate) and other fixed dose combinations are the most promising molecules that are currently in the late stage pipeline.

These molecules promise a substantial advantage over existing treatment options in terms of efficacy and safety, along with a longer duration of action and less frequent of dosing. The development pipeline is filled with first-in-class molecules targeting the underlying pathophysiology of the disease.

GlobalData, the industry analysis specialist, has released a new report, “Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global COPD market. The report identifies the key trends shaping and driving the global COPD market. The report also provides insights on the prevalent competitive landscape and the companies expected to significantly alter the market landscape. Most importantly, the report provides valuable insights on the pipeline products within the global COPD sector.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Chro...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.